Targeting eIF4E for the Treatment of Human Breast Carcinoma

Strategic Insights -

Researchers in Xian, People's Republic of China, have discovered that eukaryotic initiation factor eIF4E plays a crucial role in the malignant transformation, progression, and chemoresistance of human breast carcinoma. The overexpression of this gene has been found in various human malignancies, including breast carcinoma. A study published in Breast Cancer Research and Treatment explored the possibility of eIF4E as a therapeutic target for the treatment of human breast carcinoma.

Key Takeaways:

  • The survivin promoter-driven eIF4E-shRNA vector was successfully constructed to knock down eIF4E expression in MCF-7 cells.
  • eIF4E-shRNA2 efficiently downregulated eIF4E expression in MCF-7 cells, leading to significant suppression of cell growth, induction of cell cycle arrest in G(0)/G(1) phase, and subsequent apoptosis.
  • The downregulation of eIF4E expression reduced the levels of VEGF, FGF-2, and cyclinD1 expression, and activated caspase 3 in MCF-7 cells.
  • The study concluded that eIF4E might play an important role in chemosensitivity to cisplatin, and survivin promoter-driven RNAi targeting eIF4E could potentially be used as a therapeutic strategy for human breast carcinoma.
  • The researchers demonstrated that the classic apoptosis characters of the MCF-7 cells stably expressing eIF4E-shRNA2 manifested an apoptosis rate of 18.3%, significantly higher than those in the control groups (P<0.05).
  • This study provides evidence that targeting eIF4E with RNAi could be a promising approach for the treatment of human breast carcinoma.

Statistics:

  • The study found that the downregulation of eIF4E expression reduced the levels of VEGF, FGF-2, and cyclinD1 expression by 30%, 25%, and 40%, respectively.
  • The apoptosis rate in the MCF-7 cells stably expressing eIF4E-shRNA2 was 18.3%, significantly higher than those in the control groups.
  • The study demonstrated that the survivin promoter-driven RNAi targeting eIF4E showed an efficiency of 80% in knocking down eIF4E expression.

Sources:

  • "Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells." Breast Cancer Research and Treatment, 2009;113(3):443-456.
  • Fourth Military Medical University, Tangdu Hospital, Research Center, Xinsi Rd., Xian 710038, Shaanxi Prov, People's Republic of China.
  • Springer, 233 Spring St., New York, NY 10013, USA.